Additionally, apoB measurement is cost-effective, does not require fasting, and remains reliable even in the presence of hypertriglyceridemia or reduced LDL-C levels due to lipid lowering therapy (Glavinovic et al., 2022). This evidence concerns the gene APOB and hypertriglyceridemia.